Description

Simple

A medication used to treat an inflammatory skin condition called psoriasis that causes thick, red patches.

Clinical

A topical synthetic vitamin D2 derivative used in the treatment of plaque psoriasis.

Overview

Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Pharmacology

Indication

For the treatment of moderate plaque psoriasis in adults.

Pharmacodynamic

Calcipotriene is a synthetic analog of vitamin D. In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin.

Mechanism of action

The precise mechanism of calcipotriol in remitting psoriasis is not well-understood, however, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor while being less than 1% the activity in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the s... Read more

Absorption

Clinical studies with radiolabeled ointment indicate that approximately 6% (+3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques or 5% (+2.6%, SO) when applied to normal skin.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

The active form of the vitamin, 1,25-dihydroxy vitamin D3 (calcitriol), is known to be recycled via the liver and excreted in the bile. There is evidence that maternal 1,25-dihydroxy vitamin D3 (calcitriol) may enter the fetal circulation, but it is not known whether it is excreted in human milk.

Toxicity

Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Hypercalcemia
      • Drugbank Id: DBCOND0003950
  • Regions: US
  • Patient Conditions:
      • Name: Use in the face
      • Drugbank Id: DBCOND0108393
  • Regions: US
  • Patient Conditions:
      • Name: Vitamin D toxicity
      • Drugbank Id: DBCOND0108366

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Calcipotriol
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Calcium
The risk or severity of adverse effects can be increased when Calcium is combined with Calcipotriol.
Calcium acetate
The risk or severity of adverse effects can be increased when Calcium acetate is combined with Calcipotriol.
Calcium carbonate
The risk or severity of adverse effects can be increased when Calcium carbonate is combined with Calcipotriol.
Calcium cation
The risk or severity of adverse effects can be increased when Calcium cation is combined with Calcipotriol.
Calcium chloride
The risk or severity of adverse effects can be increased when Calcium chloride is combined with Calcipotriol.
Calcium citrate
The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Calcipotriol.
Calcium glubionate anhydrous
The risk or severity of adverse effects can be increased when Calcium glubionate anhydrous is combined with Calcipotriol.
Calcium glucoheptonate
The risk or severity of adverse effects can be increased when Calcium glucoheptonate is combined with Calcipotriol.
Calcium gluconate
The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Calcipotriol.
Calcium lactate
The risk or severity of adverse effects can be increased when Calcium lactate is combined with Calcipotriol.
Calcium lactate gluconate
The risk or severity of adverse effects can be increased when Calcium lactate gluconate is combined with Calcipotriol.
Calcium levulinate
The risk or severity of adverse effects can be increased when Calcium levulinate is combined with Calcipotriol.
Calcium pangamate
The risk or severity of adverse effects can be increased when Calcium pangamate is combined with Calcipotriol.
Calcium Phosphate
The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Calcipotriol.
Calcium polycarbophil
The risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with Calcipotriol.
Fosphenytoin
The serum concentration of Calcipotriol can be decreased when it is combined with Fosphenytoin.
Phenytoin
The serum concentration of Calcipotriol can be decreased when it is combined with Phenytoin.